← All tickers

Is CADL Worth Buying in 2026?

Candel Therapeutics, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-04-19

Here’s whether Candel Therapeutics, Inc. Common Stock (CADL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.

🔵
Neutral

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +40.6%. Concerns: 50-day MA is falling (-3.17% over 10 days); RSI 79 — overbought, elevated pullback risk. Currently 12.1% off its 52-week high. Score: +2/7.

Ready to act on this? 📈 Trade on Webull

CADL is in a confirmed uptrend, trading above both its 50-day ($5.15) and 200-day ($5.51) moving averages. With an RSI of 79.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +40.6% compares to +35.1% for SPY (beat the market by 5.5%).

$10,000 invested 1 year ago → $14,062 today
vs. S&P 500 (SPY) — same period beat market by 5.5%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($5.51)
✓Above 50-day MA ($5.15)
!RSI(14) neutral zone (30–70) — currently 79.3
✓Positive return (+40.6%)
!Within 10% of period high (−12.1%)
Period Range $6.37
$4.34 $7.25
RSI (14) 79.3
0 · OversoldOverbought · 100

Key Metrics

Price$6.37
Period Return+40.6%
Period High$7.25
Period Low$4.34
Drawdown−12.1%
MA-50$5.15
MA-200$5.51
RSI (14)79.3
Avg Volume (30d)1.3M
vs. SPYbeat by 5.5%
Return Rank#419 of 996

Trade CADL

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers